Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan May 3, 2013 11:35 PM Flag

    Update from S&P May 1

    May 1, 2013
    11:11 am ET ... S&P MAINTAINS BUY OPINION ON SHARES OF VERTEX
    PHARMACEUTICALS (VRTX 78.02****):We keep our target price at $100. Q1
    adjusted loss of $0.10, vs. $0.43 EPS inclusive of stock option expense, is
    narrower than our $0.16 loss view, on higher revenues. However, sales declined
    25% due to waning Incivek demand ahead of new expected hepatitis C entrants.
    We narrow our '13 adjusted loss forecast $0.06 to a $0.77 loss.We remain
    confident in VRTX's cystic fibrosis program, with key F508del mutation sub-group
    on track for '14 FDA filing. With $1.24B in cash, we think VRTX is on solid financial
    footing to invest in its pipeline for long-term growth. /S.Silver

 
VRTX
133.75+3.64(+2.80%)Aug 27 3:59 PMEDT